The Center for Biosimilars® recaps the top news for the week of October 15, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of October 15.
Number 5: During the American College of Rheumatology Annual Meeting, several research teams will present findings on nonmedical switching from reference products to biosimilars in the European Context.
Number 4: Ireland’s Medicines Management Program has opened a consultation related to its roadmap for prescribing best-value biologics in the Irish healthcare setting. The MMP will review the use of currently reimbursed anti-tumor necrosis factor therapies, which represent the highest-expenditure category for Ireland’s reimbursement plan.
Number 3: During a speech earlier this week, HHS Secretary Alex Azar proposed requiring drug companies to include the list price of a drug paid for by Medicare or Medicaid in direct-to-consumer television advertising.
Number 2: This week, UnitedHealthcare rolled out some of the changes it will be implementing in its Medicare Advantage plans beginning January 1, 2019, including listing 3 biosimilars as preferred treatments.
Number 1: Sandoz announced this week that its biosimilar adalimumab, Hyrimoz, became available in the United Kingdom, and Amgen announced that it will begin making its Amgevita available in multiple European markets. One day after the announcements from Sandoz and Amgen, Samsung Bioepis announced that it has launched its own biosimilar, Imraldi.
Finally, last week, our e-newsletter asked if Momenta’s change of direction signals trouble for the biosimilars market.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.